about
MicroRNAs Expressed during Viral Infection: Biomarker Potential and Therapeutic ConsiderationsTargeted delivery of mutant tolerant anti-coxsackievirus artificial microRNAs using folate conjugated bacteriophage Phi29 pRNACaspase-2 mediated apoptotic and necrotic murine macrophage cell death induced by rough Brucella abortusRNA Interference inhibits hepatitis B virus of different genotypes in vitro and in vivoDrug delivery-mediated control of RNA immunostimulationIdentification of an effective siRNA target site and functional regulatory elements, within the hepatitis B virus posttranscriptional regulatory element.Antiviral treatment of chronic hepatitis B virus (HBV) infectionsStrategies to eliminate HBV infection.Small interfering RNAs induce target-independent inhibition of tumor growth and vasculature remodeling in a mouse model of hepatocellular carcinomaShort hairpin RNA targeting 2B gene of coxsackievirus B3 exhibits potential antiviral effects both in vitro and in vivo.Prospects for inhibiting the post-transcriptional regulation of gene expression in hepatitis B virus.Hepatitis B virus-specific miRNAs and Argonaute2 play a role in the viral life cycle.RNA interference for improving the outcome of islet transplantation.Present and future therapies of hepatitis B: From discovery to cureCoenzyme Q10 rescues ethanol-induced corneal fibroblast apoptosis through the inhibition of caspase-2 activation.Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infectionNF-kappaB signaling, liver disease and hepatoprotective agents.Aptamer-based therapeutics: new approaches to combat human viral diseasesLentiviral delivery of short hairpin RNAsAAV-mediated gene therapy for liver diseases: the prime candidate for clinical application?Leveraging therapeutic potential of multi-targeted siRNA inhibitors.Countering hepatitis B virus infection using RNAi: how far are we from the clinic?Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy.MicroRNAs, stem cells and cancer stem cells.Interplay between hepatitis B virus and the innate immune responses: implications for new therapeutic strategies.Viral life cycle of hepatitis B virus: Host factors and druggable targets.Treatment of hepatitis B virus: an update.Eradication Strategies for Chronic Hepatitis B Infection.Study on 2-arylthio-5-iodo pyrimidine derivatives as novel nonnucleoside inhibitors against hepatitis B virus DNA replication.Lipid nanoparticle delivery systems for siRNA-based therapeutics.Controllable inhibition of hepatitis B virus replication by a DR1-targeting short hairpin RNA (shRNA) expressed from a DOX-inducible lentiviral vector.Cationic lipid-coated gold nanoparticles as efficient and non-cytotoxic intracellular siRNA delivery vehicles.Design of potential siRNA molecules for T antigen gene silencing of Merkel Cell Polyomavirus.Design of potential siRNA molecules for hepatitis delta virus gene silencing.Are RNA Viruses Candidate Agents for the Next Global Pandemic? A Review.RNA interference: a promising approach for the treatment of viral hepatitis.Inhibition of hepatitis B Virus replication by hepatocyte nuclear factor 4-alpha specific short hairpin RNA.The design of optimal therapeutic small interfering RNA molecules targeting diverse strains of influenza A virus.A siRNA system based on HSP70 promoter results in controllable and powerful gene silencing by heat-induction.Drugs in Development for Hepatitis B.
P2860
Q26773183-4CF93FCC-BFC4-4A95-A3D0-D600CE40FCECQ28478596-2CAA7973-DE7B-4565-AEB1-C969DCD97187Q33497936-E0870163-AB79-4FAF-B026-655ACEB1D592Q33653027-4F8AB6EA-2E54-4EE1-BA2E-4C10EC468A60Q33713938-740D4A3C-AA88-4A96-A60B-8BABAB1FA58BQ34156859-643746B6-A8F4-456A-ACA9-95E942ADB616Q34223779-4A8712C9-9378-4DFC-82B4-179207B810EAQ34308129-A649D632-B052-44BA-B3DC-110E3ECE35B0Q34358256-30D8836E-A99B-476E-B222-9023D9283771Q34366003-CE897B79-1969-44E3-815F-8577D36A1857Q34428554-5E585DBD-85D2-4E94-8E3F-7C0214B1C128Q34455269-12E2FD50-553F-4425-810D-18C5E6726207Q34729434-598FAB2E-3E52-4977-A540-F74DFA11BA06Q36378278-4305578C-14F9-49AA-B659-9BAC244D0465Q36796784-D75C3F62-D80B-4730-AC25-B216AD8923A1Q36883851-D0136C27-1F9F-4A7F-8BD9-209604F5991EQ37302741-84A085C0-DBA0-4672-A416-BB7A64DD5901Q37415958-FB19417A-997D-439C-9DA3-42433F5387FCQ37430557-856BF706-945A-410B-9AC0-16E2718173F2Q37825907-75D41F15-4FC3-4739-945F-8D302E74628CQ37855818-5F519834-DE7E-4865-BCED-E1A29996BA4EQ37931159-64BA1766-A02D-4993-B144-4118A68FD613Q38037048-022957CD-03BC-4CFE-AA3E-890F427B3FA7Q38044902-91739444-A3B5-4B0E-84A9-1E7D3B125BD2Q38180983-63439DCF-525C-4BFB-8B1C-53E06643051EQ38699649-B786E827-3BE6-41E2-8405-96FFA3384140Q38794446-F6C92953-9DE0-4453-961B-128D068FB843Q38837065-EDD310CE-6FD3-4BB0-8B0B-F3C48381A36AQ38867984-1FF74410-04CB-4B31-8AE0-570FB1C3FA69Q39027758-C47641B1-6AD2-4AB1-80D9-02D059D638A2Q39196891-E14415ED-210B-49D5-B4DD-2EF86F227BA9Q39490162-53C62A5F-9E81-4A46-A1AD-9AFC59536C1DQ41501331-890B265F-CC12-40A8-BC0B-1127DE41968EQ41841424-21C9A4C1-A123-411C-9FB9-2EADAE1F7CDAQ41922832-F0DEBBA7-BF0E-4310-A24E-B00C63613D72Q42096848-B1C45A48-8094-492A-9B8D-DEBF196FB6A0Q45359603-E7333FB1-CFF5-40C4-9C9A-82B096D33A16Q45362584-520F0458-6CE4-4D3D-8BAD-7510E2A84CF6Q45855258-852BFC28-53FB-4951-9C68-6F40183AF681Q52764230-3DCD51F9-2E68-47E2-AEB5-E9030391D1F9
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
RNAi for treating hepatitis B viral infection.
@ast
RNAi for treating hepatitis B viral infection.
@en
type
label
RNAi for treating hepatitis B viral infection.
@ast
RNAi for treating hepatitis B viral infection.
@en
prefLabel
RNAi for treating hepatitis B viral infection.
@ast
RNAi for treating hepatitis B viral infection.
@en
P2093
P2860
P1476
RNAi for treating hepatitis B viral infection.
@en
P2093
Guofeng Cheng
Ram I Mahato
P2860
P356
10.1007/S11095-007-9504-0
P577
2007-12-12T00:00:00Z
2008-01-01T00:00:00Z